Table 1.
AIB1 mRNA (n = 185) | ||||
---|---|---|---|---|
low | high | p-value | ||
Age | ||||
≤ 50 | 59 | 39 | ||
> 50 | 52 | 35 | 0.54 | |
Histological type | ||||
IDC | 107 | 66 | ||
non-IDC | 4 | 8 | 0.05 | |
Histological grade | ||||
well | 41 | 15 | ||
moderate | 47 | 41 | ||
severe | 23 | 18 | 0.05 | |
T stage | ||||
T1 | 69 | 29 | ||
T2 | 38 | 41 | ||
T3 | 4 | 4 | 0.01 | |
Lymph node metastasis | ||||
negative | 59 | 46 | ||
positive | 51 | 28 | 0.16 | |
Stage | ||||
T1 | 48 | 23 | ||
T2 | 41 | 37 | ||
T3 | 19 | 14 | ||
T4 | 3 | 0 | 0.13 | |
ER | ||||
negative | 30 | 27 | ||
positive | 81 | 47 | 0.12 | |
PR | ||||
negative | 31 | 27 | ||
positive | 80 | 47 | 0.14 | |
HER2 | ||||
negative | 85 | 53 | ||
positive | 26 | 21 | 2.28 | |
AR | ||||
negative | 19 | 5 | ||
positive | 67 | 38 | 0.11 | |
DAX-1 | ||||
negative | 25 | 7 | ||
positive | 61 | 36 | 0.08 |
AIB1: amplified in breast cancer I; IHC: immunohistochemistry; IDC: invasive ductal carcinoma; ER: estrogen receptor; PR: progesterone receptor; and AR: androgen receptor.